NEW YORK (May 21, 2007) -- NewYork-Presbyterian Hospital/Columbia University Medical Center physician-scientists are presenting exciting new research at the 2007 American Urological Association (AUA) annual meeting in Anaheim, Calif., May 1924. Among the most significant presentations are the following:
Female Sexual Dysfunction in Urologic Patients: Findings From the New York/New Jersey Metropolitan Area 
Authors: Harry Fisch, M.D., Ithor S. Sawczuk, M.D., et al.
Investigators assessed the prevalence and risk factors of female sexual dysfunction (FSD) in urologic patients from the New York/New Jersey metropolitan area. Based on surveys completed by 587 female urological patients, the study found female sexual dysfunction in urologic patients is prevalent in all age groups, with age, menopausal status and the usage of anti-depression medication (SSRIs) functioning as significant risk factors.
Satraplatin Significantly Improves Progression Free Survival (PFS) and Pain Control in Patients with Advanced Hormone-Refractory Prostate Cancer (HRPC): Preliminary Results From the Phase III SPARC Trial 
Authors: Daniel P Petrylak, M.D., et al
Pain control constitutes a major clinical challenge in the treatment of metastatic Hormone-Refractory Prostate Cancer (HRPC) and is a relevant therapeutic goal in this population. Satraplatin (S) is a novel oral platinum compound with demonstrated antitumor activity in a variety of tumors, including HRPC. The SPARC trial is a large, double-blind, placebo-controlled, phase III study, evaluating S in combination with prednisone (P) for the treatment of HRPC patients who have failed one prior chemotherapy regimen. The study found that oral satraplatin is well tolerated and has clinically relevant activity in patients with metastatic HRPC.
Increasing Body Mass Index Is Not an Independent Predictor of Outcome Following Radical Prostatecomy 
Contact: Bryan Dotson
New York- Presbyterian Hospital/Columbia University Medical Center